Anti-CD37 antibody-drug conjugate

The present invention provides: an antibody that specifically binds to CD37-positive tumor cells such as B-cell malignant lymphoma; an antibody-drug conjugate that contains said antibody; a pharmaceutical composition that employs said antibody and that exhibits a therapeutic effect on a tumor; a tum...

Full description

Saved in:
Bibliographic Details
Main Authors SHINJO, YUJI, GOTO, RIKI, TERAUCHI, TOMOKO, SHUCHI, YUSUKE, SUGAWARA, HAJIME
Format Patent
LanguageChinese
English
Published 01.08.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides: an antibody that specifically binds to CD37-positive tumor cells such as B-cell malignant lymphoma; an antibody-drug conjugate that contains said antibody; a pharmaceutical composition that employs said antibody and that exhibits a therapeutic effect on a tumor; a tumor treatment method employing said pharmaceutical composition; a method for producing said antibody; a method for producing said antibody-drug conjugate; and so forth. Provided is an anti-CD37 antibody-drug conjugate in which a drug linker, which is represented by the formula below, and an antibody are bonded by means of a thioether bond (in the formula, A indicates the position at which the linker is bonded with the antibody). Specifically, provided are: a humanized anti-CD37 antibody that exhibits an internalization activity; and an antibody-drug conjugate that contains said antibody.
Bibliography:Application Number: TW202211139216